Bayer, Plaintiffs Seek Delay in $7.25 Billion Roundup Settlement Hearing

Bayer AG's Monsanto unit and attorneys for plaintiffs have jointly requested a postponement of a key court hearing to approve a $7.25 billion settlement resolving thousands of lawsuits alleging the Roundup weedkiller causes cancer. The parties have asked a Missouri judge to move the hearing from its scheduled date of August 19 to September 10.

Reason for the Delay

In the joint request filed with the court, the parties stated that the delay is needed to allow for additional administrative processing. According to a statement from Bayer, the extension will provide the settlement administrator sufficient time to process "opt-out revocation requests" that have been received.

This administrative step involves handling requests from individuals who may have initially chosen to opt out of the settlement but have since decided to participate.

Ad

Context of the Litigation

The hearing is a critical step toward finalizing the multi-billion dollar agreement, which aims to address a significant portion of the U.S. litigation against Bayer. The lawsuits claim that glyphosate, the active ingredient in Roundup, is carcinogenic.

For investors, the long-running Roundup litigation has been a major financial overhang for Bayer since its acquisition of Monsanto. A successful finalization of this settlement would mark a significant milestone in resolving the company's legal liabilities related to the product.